This paper is only available as a PDF. To read, Please Download here.
Abstract
Serious anaemia can be induced by human parvovirus B19 (HPV) infection in immuno-compromised
patients or subjects with an haemolytic disorder. Routine inactivation procedures
are insufficient to neutralize the virus, but screening for HPV is an effective means
to avoid transmission by transfusion of blood components.
In the present study, we have compared for the first time the IgG and IgM seroprevalence
in a North African (Tunisian) and Western European (Belgian) population of blood donors.
The prevalence of HPV-specific IgM was less than 2% in both populations, pointing
to the absence of an epidemic. The prevalence HPV IgG was significantly (p<0.01) higher in Belgium (74%) than in Tunisia (65%), without any relationship with
age or sex. This finding may suggest a south-north gradient of this infectious disease.
Since the presence or absence of HPVspecific antibodies does not preclude transfusional
transmission, screening for the virus itself should be done to avoid iatrogenic infection
in HPV-naive subjects at risk. In view of the different transfusion policies in Belgium
and Tunisia, a strategy for each of both countries is proposed.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Parvovirus-like particles in human sera.Lancet. 1975; 1: 72-73
- Parvovirus infections and hypoplastic crisis in sickle-cell anaemia.Lancet. 1981; ?: 664-665
- Sero-epidemiology of human parvovirus infection in homozygous sickle cell disease (abstract).Blood. 1992; 50: 10A
- Hematologic and hematopoietic consequences of B19 parvovirus infection.Semin Hematol. 1988; 25: 159-172
- Human parvovirus infection in children and severe anaemia seen in an area endemic for malaria.J Trop Med Hyg. 1990; 93: 67-70
- A human parvovirus-like virus inhibits haematopoietic colony formation in vitro.Nature. 1983; 302: 426-429
- Parvovirus infection and its treatment.Clin Exp Immunol. 1996; 104: 26-30
- Le parvovirus B19.in: Lefrère JJ Les Virus Transmissibles par le sang. John Libbey Eurotext, Montrouge, France1996: 169-185
- Prospective study of human parvovirus (B19) infection in pregnancy.Br Med J. 1990; 300: 1166-1170
- Human parvovirus, the cause of erythema infectiosum (fifth disease)?.Lancet. 1983; 1: 1378
- Clinical manifestation of human parvovirus B19 in adults.Arch Intern Med. 1989; 149: 1153-1156
- Human parvovirus arthropathy.Lancet. 1985; 1: 419-422
- Human parvovirus infection in homozygous sickle cell disease.Lancet. 1993; 341: 1237-1240
- Human parvovirus B19 specific IgG, IgA and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum.J Med Virol. 1991; 35: 110-115
- Parvoviruses.in: Fields BN Knipe DM Howley PM Fields Virology. 3rd edn. Lippincott-Raven Publishers, Philadelphia1996: 2199-2220
- Persistent parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS.Ann Intern Med. 1990; 113: 926-933
- Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy.J Infect Dis. 1993; 168: 101-105
- Parvovirus-B19-related pancytopenia in children with HIV infection.Lancet. 1992; 340: 115
- Parvovirus B19 in HIV infection: A treatable cause of anemia.Pathology. 1996; 28: 277-280
- Management of persistent B19 parvovirus infection in AIDS.Br Med J. 1995; 91: 90-92
- Prevalence of parvovirus B 19 infection in patients infected with Human Immunodeficiency Virus.Clin Infect Dis. 1996; 23: 1255-1260
- Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy.N Engl J Med. 1989; 321: 519-523
- Persistent B19 parvovirus infection as a cause of severe chronic anemia in children with acute lymphocytic leukaemia.Lancet. 1988; 2: 1159-1162
- Parvovirus B19 for the hematologist.Am J Hematol. 1992; 39: 119-130
- Experimental parvoviral infection in humans.J Infect Dis. 1985; 152: 257-265
- Detection of parvovirus B19 in donated blood: a model system for screening by Polymerase Chain Reaction.J Clin Microbiol. 1993; 31: 323-328
- Prenatal diagnosis of intra-uterine infection with parvovirus B19 by the polymerase chain reaction technique.Clin Infect Dis. 1992; 14: 149-155
- Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by nested polymerase chain reaction.Br Med J. 1992; 81: 407-412
- Incidence of human parvovirus B19 DNA detection in blood donors.Br Med J. 1995; 91: 1017-1018
- Enzyme-linked immunosorbent assay for IgG and IgM antibodies against human parvovirus B19: use of monoclonal antibodies and viral antigen propaged in vitro.J Virol Meth. 1989; 26: 171-182
- Seroprevalence of human parvovirus B19 infection in Sao Tome and Principe, Malawi and Mascarene Island.Zbl Bakt. 1989; 271: 231-236
- Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV).J Hyg Camb. 1983; 91: 113-136
- Parvovirus B19 clearance from peripheral blood after acute infection.J Infect Dis. 1995; 172: 1360-1363
- Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19.J Clin Microbiol. 1995; 33: 1363-1365
- The seroprevalence of antibody to human parvovirus B19 in England and Wales.J Med Microbiol. 1988; 25: 151-153
- Human parvovirus B19 infections in the UK 1984–1986.Lancet. 1987; 1: 738-739
- Detection of antibodies and antigens of human parvovirus B19 by Enzyme-Linked ImmunoSorbent Assay.J Clin Microbiol. 1986; 24: 522-526
- Parvovirus B19: an expanding spectrum of disease.Br Med J. 1995; 311: 1549-1551
- Persistent B19 parvovirus infection: a treatable cause of anemia in AIDS.Ann Intern Med. 1990; 113: 926-933
- Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy.N Engl J Med. 1989; 321: 519-523
- Risk analysis to assess potential value of Gene Amplification Testing for improving plasma product safety.in: 2nd edn. European Plasma Fractionation Association Annual Report. 1995–1996: 8-9
Article info
Publication history
Accepted:
July 3,
1997
Received:
April 29,
1997
Identification
Copyright
© 1997 Published by Elsevier Inc.
